RMC-6236-304/RASolute 304

RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

This is a global, randomized, open-label, Phase 3 study designed to evaluate whether treatment with daraxonrasib will improve disease-free survival (DFS) compared to SOC observation in patients with resected PDAC who have completed neoadjuvant and/or adjuvant chemotherapy.

ClinicalTrials.gov Link: https://clinicaltrials.gov/study/NCT07252232?viewType=Card&id=RMC-6236-304&rank=1

Locations: Hartford Hospital and Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut

Contact: Holly Maheu: holly.maheu@hhchealth.org